SCHEMBL519182

SCHEMBL519182

CCCCCCCCCC(CCCCCCCC=CCO)OC(CCCCCCCC=CCO)CCCCCCCCC

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
CNR1 P21554 2/20 0.46
CNR2 P34972 2/20 0.46
FAAH O00519 3/20 0.42
TRPV1 Q8NER1 1/20 0.42
PRKCE Q02156 1/20 0.42
PRKCQ Q04759 1/20 0.42
PRKCD Q05655 1/20 0.42
PRKCA P17252 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
FFAR1 O14842 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7994536 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL27586618 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL251323 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL170304 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL7072490 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL519027 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL251871 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL438865 1.00 ALDH1A1 (0.46) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL251249 0.96 ALDH1A1 (0.42) ALDH1A1CNR1CNR2FAAHTRPV1
SCHEMBL250711 0.93 ALDH1A1 (0.39) ALDH1A1CNR1CNR2FAAHPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080181914-A1 NOVEL VACCINE COMPOSITION SAECHSISCHES SERUMWERK DRESDEN 2008-07-31 US claimed
EP-1214053-A1 ADJUVANT COMPRISING A POLYOXYETHYLENE ALKYL ETHER OR ESTER AND AT LEAST ONE NONIONIC SURFACTANT SMITHKLINE BEECHAM BIOLOGICALS s.a. (BE) 2002-06-19 EP claimed
WO-2001021152-A1 ADJUVANT COMPRISING A POLYXYETHYLENE ALKYL ETHER OR ESTER AND AT LEAST ONE NONIONIC SURFACTANT SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 2001-03-29 WO claimed
US-12042531-B2 Breast and ovarian cancer vaccines UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2024-07-23 US disclosed
WO-2024118234-A2 RATIONALLY DESIGNED MYCOPLASMA GALLISEPTICUM SUBUNIT VACCINE UNIVERSITY OF CONNECTICUT (US) 2024-06-06 WO disclosed
CN-115190911-B Composition having immunogenicity against SARS coronavirus 2, its preparation method and use 港大科桥有限公司 2024-04-23 CN disclosed
CN-116635068-A Compositions having immunogenicity against influenza and SARS coronavirus 2, methods of making and using the same 港大科桥有限公司 2023-08-22 CN disclosed
CN-109248313-B Compositions for immunization against staphylococcus aureus 葛兰素史密丝克莱恩生物有限公司 2023-01-17 CN disclosed
CN-115190911-A Composition with immunogenicity to SARS coronavirus 2, its preparation method and use 港大科桥有限公司 2022-10-14 CN disclosed
CN-115175924-A PD-1 based vaccines against coronavirus infection 港大科桥有限公司 2022-10-11 CN disclosed
US-11185578-B1 Breast and ovarian cancer vaccines UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2021-11-30 US disclosed
WO-2002087494-A2 NOVEL VACCINE GLAXOSMITHKLINE BIOLOGICALS, SA (BE) 2002-11-07 WO disclosed
WO-2002074336-A2 INFLUENZA VACCINE FORMULATIONS FOR INTRADERMAL DELIVERY GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2002-09-26 WO disclosed
WO-2002067983-A1 NOVEL VACCINE GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2002-09-06 WO disclosed
EP-1214053-A1 ADJUVANT COMPRISING A POLYOXYETHYLENE ALKYL ETHER OR ESTER AND AT LEAST ONE NONIONIC SURFACTANT SMITHKLINE BEECHAM BIOLOGICALS s.a. (BE) 2002-06-19 EP disclosed
EP-1214054-A1 INTRANASAL INFLUENZA VIRUS VACCINE SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) (BE) 2002-06-19 EP disclosed
WO-2002028422-A2 SPLIT ENVELOPED VIRUS PREPARATION FOR INTRANASAL DELIVERY GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2002-04-11 WO disclosed
WO-2002028426-A1 SPLIT ENVELOPED VIRUS PREPARATION GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) 2002-04-11 WO disclosed
WO-2001021152-A1 ADJUVANT COMPRISING A POLYXYETHYLENE ALKYL ETHER OR ESTER AND AT LEAST ONE NONIONIC SURFACTANT SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 2001-03-29 WO disclosed
WO-2001021151-A1 INTRANASAL INFLUENZA VIRUS VACCINE SMITHKLINE BEECHAM BIOLOGICALS S.A. (BE) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080181914-A1 NOVEL VACCINE COMPOSITION TTPA, TTR, STARD7 ALDH1A1 1609/4885CNR1 2602/4885CNR2 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.